Acumen completes enrollment of ALTITUDE-AD Phase 2 trial

Acumen (ABOS) Pharmaceuticals announced the completion of enrollment in its ALTITUDE-AD Phase 2 trial of sabirnetug in patients with early Alzheimer’s disease. Acumen completed enrollment ahead of schedule and plans to report topline results, including efficacy and safety data, in late 2026. “We are pleased to complete enrollment for our Phase 2 ALTITUDE-AD trial of sabirnetug,” said Daniel O’Connell, President and Chief Executive Officer of Acumen. “Achieving this milestone is a testament to the significant interest in our approach from both patients and the scientific community, and we are grateful to all the participants, investigators and trial sites, and our clinical team for enabling us to complete enrollment efficiently. We look forward to sharing topline results in late 2026 and advancing sabirnetug as a next-generation treatment for Alzheimer’s disease.”